Short Interest in Onconetix, Inc. (NASDAQ:ONCO) Increases By 365.3%

Onconetix, Inc. (NASDAQ:ONCO) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 266,600 shares, an increase of 365.3% from the December 31st total of 57,300 shares. Approximately 7.6% of the company’s stock are sold short. Based on an average daily volume of 5,240,000 shares, the short-interest ratio is currently 0.1 days.

Onconetix Stock Performance

Shares of Onconetix stock traded down $0.04 during midday trading on Tuesday, hitting $0.60. The company had a trading volume of 3,222,243 shares, compared to its average volume of 14,808,322. Onconetix has a 52-week low of $0.32 and a 52-week high of $21.40. The company has a 50 day moving average of $0.59 and a 200 day moving average of $3.39.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings data on Monday, December 9th. The company reported ($2.24) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Onconetix

An institutional investor recently raised its position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Onconetix, Inc. (NASDAQ:ONCO) by 83.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 562,691 shares of the company’s stock after purchasing an additional 256,612 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 76.04% of Onconetix worth $2,926,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 23.89% of the company’s stock.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.